Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139971

Published: 2020

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Matthieu Mosca, PhDstudent, Lamia Lamrani, PhD, Christophe Marzac, MD, Amandine Tisserand, Valérie Edmond, PhD, Tracy Dagher, PhDstudent, Mira El-Khoury, PhD, Caroline Marty, PhD, Hugo Campario, PharmD, Nicole Casadevall, MD, Eric Solary, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD PhD, Isabelle Plo, PhD

Blood (2018) 132 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2018-99-114744

Published: 2018

Journal Articles

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Blood (2018) 132 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2018-99-110366

Published: 2018

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Pierre Hirsch, MD, Myriam Labopin, Christophe Marzac, MD, Anne-Claire Mamez, MD, Ruoping Tang, Françoise Isnard, MD, Simona Lapusan, Anne Vekhoff, MD, Norbert C Gorin, MD, Jean-Pierre Marie, Mohamad Mohty, Ollivier Legrand, MD PhD

Blood (2014) 124 (21): 1033.

https://doi.org/10.1182/blood.V124.21.1033.1033

Published: 2014

Journal Articles

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Emmanuelle Kempf, Pierre Hirsch, Myriam Labopin, Christophe Marzac, MD, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, MD, Mohamad Mohty, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2013) 122 (21): 2658.

https://doi.org/10.1182/blood.V122.21.2658.2658

Published: 2013

Journal Articles

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Marguerite Vignon, Dorota Jeziorowska, Pierre Hirsch, MD, Ollivier Legrand, MD, PhD, Nicole Casadevall, MD, Francois Delhommeau, PharmD, PHD, Christophe Marzac, MD

Blood (2012) 120 (21): 1745.

https://doi.org/10.1182/blood.V120.21.1745.1745

Published: 2012

Journal Articles

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

Pierre Hirsch, Ruoping Tang, Christophe Marzac, MD, Fanny Fava, Jean-Yves Perrot, Françoise Isnard, MD, Jean-Pierre Marie, Ollivier Legrand, MD, PhD

Blood (2012) 120 (21): 4909.

https://doi.org/10.1182/blood.V120.21.4909.4909

Published: 2012

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with a Pediatric Protocol: Results of a Pilot Study.

Stephanie Haiat, MD, Anne Vekhoff, MD, Christophe Marzac, MD, OrsAnton Calendini, MD, Simona Lapusan, MD, Zora Marjanovic, MD, Bernard Rio, MD, Jean-Pierre Marie, MD, Ollivier Legrand, MD

Blood (2007) 110 (11): 2822.

https://doi.org/10.1182/blood.V110.11.2822.2822

Published: 2007

Journal Articles

Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.

Jean-Jacques Kiladjian, MD, Francisco Cervantes, MD,PhD, Frank W.G. Leebeek, MD,PhD, Sylvie Chevret, MD,PhD, Dominique Cazals-Hatem, MD, Aurélie Plessier, MD, Christophe Marzac, MD, Bruno Cassinat, MD, Sebastian Raffa, MD, Juan Carlos Garcia-Pagan, MD,PhD, Sarwa Darwish Murad, MD,MSc, Harry L.A. Janssen, MD,PhD, Dominique Valla, MD,PhD, Nicole Casadevall, MD,PhD, Pierre Fenaux, MD,PhD

Blood (2006) 108 (11): 377.

https://doi.org/10.1182/blood.V108.11.377.377

Published: 2006

Journal Articles

JAK2 V617F in 3 Patients with Venous Thromboembolism (VTE) Followed during a Long Period of Time.

Jacqueline Conard, PhD, Christophe Marzac, MD, Fabrice Juin, PhD, Marie-Helene Horellou, MD, Ors’Antone Calendini, MD, Nicole Casadevall, MD

Blood (2006) 108 (11): 4092.

https://doi.org/10.1182/blood.V108.11.4092.4092

Published: 2006

Journal Articles

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Christophe Marzac, MD, Irene Teyssandier, MD, Jean Yves Perrot, MD, Anne Marie Faussat, MD, Ruoping Tang, PhD, Nicole Casadevall, MD, PhD, Jean Pierre Marie, MD, PhD, Ollivier Legrand, MD, PhD

Blood (2005) 106 (11): 2375.

https://doi.org/10.1182/blood.V106.11.2375.2375

Published: 2005

NARROW

Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

ATG2B/Gskip in De Novo Acute Myeloid Leukemia (AML): High Prevalence of Germline Predisposition in French West Indies and Potential Role of Overexpression in Acquired AML

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Impact of FLT3-ITD Mutational Burden in 469 Acute Myeloid Leukemia (AML) Patients

Prognostic Impact Of Body Mass Index (BMI) In Acute Myeloid Leukemia (AML)

Clinical Implications for Patients with Low JAK2V617F Allele Burden

Molecular Minimal Residual Disease After Induction Is Related to ABC Proteins' Activity and Associated with Survival in 26 Patients with NPM1 Mutated Acute Myeloid Leukemia

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with a Pediatric Protocol: Results of a Pilot Study.

Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.

JAK2 V617F in 3 Patients with Venous Thromboembolism (VTE) Followed during a Long Period of Time.

Prognosis Value of Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality, in 171 AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only